ELV250117P400000
- 14.74
- 0.000.00%
Elevance Health Newsroom
BofA Securities Maintains Elevance Health(ELV.US) With Hold Rating, Announces Target Price $465
Cautious Hold Recommendation on Elevance Health Amidst Medicare Growth and Medicaid Cost Challenges
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Raises Target Price to $512
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating
Morgan Stanley Reaffirms Their Hold Rating on Elevance Health (ELV)
Stephens Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $440
Stephens Downgrades Elevance Health to Equalweight From Overweight, Adjusts Price Target to $440 From $520
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $501
Barclays Remains a Buy on Elevance Health (ELV)
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $502
Analysts Conflicted on These Healthcare Names: Elevance Health (ELV), Agilent (A) and Insulet (PODD)
Elevance Health Is Maintained at Buy by Truist Securities
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $480
Elevance Health Analyst Ratings
Truist Securities Maintains Buy on Elevance Health, Lowers Price Target to $480
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
Elevance Health Downgraded to Equal Weight From Overweight at Morgan Stanley
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)